U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Animal Drug User Fee Act Performance - INAD H Submissions Submitted at Division Level
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Animal Drug User Fee Act Performance - INAD H Submissions Submitted at Division Level

On September 30, 2023, the fourth reauthorization of the Animal Drug User Fee Act (ADUFA), referred to as ADUFA V, was signed into law. ADUFA V amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by reauthorizing ADUFA for an additional five years (FY 2024 through FY 2028). ADUFA provides FDA with revenue to enhance the performance and predictability in review times for the animal drug industry and provides FDA with resources to improve its review of applications for new animal drugs, with the result that safe and effective new products will be more readily available.

Per the ADUFA V goals letter, beginning in FY 2024, FDA will report quarterly in FDA‐TRACK the number of H submissions submitted to each review division in the Office of New Animal Drug Evaluation. H submissions have a 100-day review clock and are submitted under Investigation New Animal Drug files in support of a meeting request, in support of a protocol, or to reach agreement on the raw data to submit in a Target Animal Safety data submission.

 

Note: Current Fiscal Year represents performance year-to-date. (10/1/2023 - 3/31/2024)

 

Division Code Code Description
DABCT Division of Animal Biotechnology and Cellular Therapies
DBISM Division of Business Information Science and Management
DCAD Division of Companion Animal Drugs
DFAD Division of Food Animal Drugs
DHFS Division of Human Food Safety
DMT Division of Manufacturing Technologies
DSS Division of Scientific Support

Download INAD H Submissions Submitted at Division Level Dataset


Note: The data provided on this website are produced on an ongoing basis for performance management purposes and are subject to change due to updates of preliminary estimates, corrections, or other reasons.

 

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top